Adapted Physical Activity in Patients With Lower Limb Peripheral Arterial Disease (ACTIV'AO)

Adapted Physical Activity in Patients With Lower Limb Peripheral Arterial Disease (ACTIV'AO)

The prevalence of peripheral arterial disease is 12.2% in France. Intermittent claudication is the most common symtom of this disease. During physical exercise, such as walking, blood oxygen (O2) requirements increase. The development of atherosclerosis in the lower limbs, causes narrowing of the arteries and limits the increase in blood flow required for muscular effort. Patients then experience muscle pain, the intensity of which gradually increases until it forces them to stop. After stopping, the pain subsides and disappears in less than 10 minutes.

The location of the pain (calves and/or thighs and/or buttocks) is related to the location of the ischemia (distal in the calf, proximal in the thigh or buttock, or proximo-distal if several locations). This can have different consequences on the biomechanical parameters of walking and muscle activity. To date, the impact of this localization on physical capacity has never been studied.

These limitations are very disabling and impact the quality of life of patients.

In addition, poor lower limb performance is associated with higher mortality. Reducing symptomatology and improving functional abilities is therefore a major issue in patients with peripheral arterial disease. This can be achieved through the practice of an Adapted Physical Activity, an essential recommendation in the care of patients with peripheral arterial disease.

Our main hypothesis is that the physical activity rehabilitation protocol "Activ'AO" will improve the functional capacities of patients with peripheral arterial disease who have followed the program with the localization of ischemia with a greater consideration than in patients in the group following a "standard" APA protocol. Improvements in functional abilities (such as walking) will lead to improvements in quality of life.

Study Overview

• Status: Recruiting
• Conditions: Peripheral Arterial Disease
• Intervention / Treatment: Other: muscle strengthening targeted on ischemic areas; Other: global muscle strenghtening

• Study Type: Interventional
• Enrollment (Estimated): 70
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Karine MONTACLAIR; Phone Number: 02 43 43 43 43; Email: kmontaclair@ch-lemans.fr
• Study Contact Backup: Name: Christelle JADEAU; Phone Number: 02 44 71 07 81; Email: cjadeau@ch-lemans.fr

Study Locations

• France
  • Le Mans, France, 72000
    • Recruiting
    • Centre Hospitalier du Mans
    • Contact: Christelle JADEAU; Phone Number: 02 44 71 07 81; Email: cjadeau@ch-lemans.fr
    • Principal Investigator: Claire NEVEUX-BRECHETEAU, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patient with Lower Limb Peripheral Arterial Disease with IPSC < 0.90, arterial stenosis in the lower limbs and intermittent claudication
• No contraindication to physical activity
• Socially insured patients over 18 ;
• Patient who has signed the consent form.

Exclusion Criteria:

• Severe or unstable cardiopulmonary pathologies, contraindicating exercise training
• Unstable angina or myocardial infarction <3 months
• Severe rheumatological pathology of the lower limbs
• Amputee of a lower or upper limb fitted with a device
• Extensive dermatosis of the lower limbs
• Known NYHA grade III or IV heart failure
• Known severe respiratory pathology
• Parkinson's disease, hemiplegia or paraplegia
• Adults subject to enhanced protection, deprived of their liberty by judicial or administrative decision
• Persons unable to consent
• Be in a period of exclusion from other interventional research.
• Any event (injury, surgery, etc.) occurring during the protocol period that could have an impact on results.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: APA with consideration of ischemia localization	Other: muscle strengthening targeted on ischemic areas; muscle strengthening targeted on ischemic areas
Experimental: APA without consideration of ischemia localization	Other: global muscle strenghtening; global muscle strenghtening

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assess efficacity of Adapted Physical Activity with localization of ischemia on maximum walking distance compared to Adapted Physical activity without localization of ischemia	The efficacity of Adapted Physical Activity was assessed by measure of maximum walking distance	12 weeks after inclusion

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assess efficacity of Adapted Physical Activity with localization of ischemia on walking abilities compared to Adapted Physical activity without localization of ischemia	The efficacity of Adapted Physical Activity was assessed by measure of walking speed with actimeter	12 weeks after inclusion
Assess efficacity of Adapted Physical Activity with localization of ischemia on static balance compared to Adapted Physical activity without localization of ischemia	The efficacity of Adapted Physical Activity was assessed by measure of balance static with stabilometry Platform.	12 weeks after inclusion
Assess quality of Life	Assess quality of life with the "Vascular Quality of Life" questionnaire, and physical activity levels with the "Global Physical Activity Questionnaire".	At week 12
Assess strength capacities	The efficacy of Adapted Physical Activity on strength capacities is measured using grip strength, dynamometers and the chair lift test	12 weeks after inclusion
Assess neuromuscular activity	The efficacy of Adapted Physical Activity on neuromuscular activity is measured using surface electromyography	12 weeks after inclusion

Collaborators and Investigators

• Sponsor: Centre Hospitalier le Mans

Study record dates

Study Major Dates

• Study Start (Actual): February 11, 2021
• Primary Completion (Estimated): November 11, 2026
• Study Completion (Estimated): November 11, 2026

Study Registration Dates

• First Submitted: March 12, 2021
• First Submitted That Met QC Criteria: March 12, 2021
• First Posted (Actual): March 16, 2021

Study Record Updates

• Last Update Posted (Actual): July 1, 2026
• Last Update Submitted That Met QC Criteria: June 30, 2026
• Last Verified: June 1, 2026

More Information

Terms related to this study

• Keywords: Peripheral Arterial Disease; Adapted Physical Activity; maximum walking distance
• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Atherosclerosis; Arteriosclerosis; Arterial Occlusive Diseases; Peripheral Vascular Diseases; Peripheral Arterial Disease
• Other Study ID Numbers: CHM-2019/S18/09

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No